Genetic polymorphisms of TP53-binding protein 1 (TP53BP1) gene and association with breast cancer risk

APMIS

Volumn 119, Issue 7, 2011, Pages 460-467

  Naidu, Rakesh ^a   Har, Yip Cheng ^b   Taib, Nur Aishah Mohd ^c  

^a MONASH UNIVERSITY MALAYSIA   (Malaysia)

^b UNIVERSITY OF MALAYA   (Malaysia)

^c UNIVERSITY MALAYA MEDICAL CENTRE   (Malaysia)

Author keywords

Breast cancer; Polymorphism; TP53 binding protein 1 (TP53BP1)

Indexed keywords

ASPARTIC ACID; BINDING PROTEIN; ESTROGEN RECEPTOR; GENOMIC DNA; GLUTAMIC ACID; THREONINE; TUMOR SUPPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN P53 BINDING PROTEIN 1; UNCLASSIFIED DRUG;

ADULT; ALLELE; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER PATIENT; CANCER RISK; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOTE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALAYSIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TUMOR DIFFERENTIATION;

ADULT; AGE OF ONSET; AGED; ALLELES; BREAST NEOPLASMS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MIDDLE AGED; NEOPLASM STAGING; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK FACTORS;

EID: 79958144452     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2011.02753.x     Document Type: Article

References (26)

1. Iwabuchi K, Bartel PL, Li B, Marraccino R, Fields S. Two cellular proteins that bind to wild-type but not mutant p53. Proc Natl Acad Sci USA 1994;91:6098-102.
2. Iwabuchi K, Li B, Massa HF, Trask BJ, Date T, Fields S. Stimulation of p53-mediated transcriptional activation by the p53-binding proteins, P53BP1 and 53BP2. J Biol Chem 1998;273:26061-68.
3. Wang B, Matsuoka S, Carpenter PB, Elledge SJ. 53BP1, a mediator of the DNA damage checkpoint. Science 2002;298:1435-38.
4. Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K, Linn S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem 2004;73:39-85.
5. Shiloh Y. ATM and related protein kinases: safe guarding genome integrity. Nat Rev Cancer 2003;3:155-68.
6. Schultz LB, Chehab NH, Malikzay A, Halazonetis TD. P53 binding protein 1 (53BP1) is an early participant in the cellular response to DNA double-strand breaks. J Cell Biol 2000;151:1381-90.
7. Rappold I, Iwabuchi K, Date T, Chen J. Tumor suppressor p53 binding protein 1 (53BP1) is involved in DNA damage-signaling pathways. J Cell Biol 2001;153:613-20.
8. Liu Y, West SC. Distinct functions of BRCA1 and BRCA2 in double-strand break repair. Breast Cancer Res 2002;4:9-13.
9. DiTullio RA Jr, Mochan TA, Venere M, Bartkova J, Sehested M, Bartek J, et al. P53BP1 functions in an ATM-dependent checkpoint pathway that is constitutively activated in human cancer. Nat Cell Biol 2002;4:998-1002.
10. Williams RS, Green R, Glover JN. Crystal structure of the BRCT repeat region from the breast cancer-associated protein BRCA1. Nat Struct Biol 2001;8:838-42.
11. Joo WS, Jeffrey PD, Cantor SB, Finnin MS, Livingston DM, Pavletich NP. Structure of the P53BP1 BRCT region bound to p53 and its comparison to the Brca1 BRCT structure. Genes Dev 2002;16:583-93.
12. Rauch T, Zhong X, Pfeifer GP, Xu X. 53BP1 is a Positive Regulator of the BRCA1 Promoter. Cell Cycle 2005;4:1078-83.
13. Ma H, Hu Z, Zhai X, Wang S, Wang X, Qin J, et al. Joint effects of single nucleotide polymorphisms in P53BP1 and p53 on breast cancer risk in a Chinese population. Carcinogenesis 2006;27:766-71.
14. Frank B, Hemminki K, Bermejo JL, Klaes R, Bugert P, Wappenschmidt B, et al. TP53-binding protein variants and breast cancer risk: a case-control study. Breast Cancer Res 2005;7:R502-5.
15. Rapakko K, Heikkinen K, Karppinen SM, Erkko H, Winqvist R. Germline alterations in the 53BP1 gene in breast and ovarian cancer families. Cancer Lett 2007;245:337-40.
16. Haffty BG, Goyal S, Kulkarni D, Green C, Vazquez A, Schiff D, et al. Evaluation of single nucleotide polymorphisms (SNPs) in the p53 binding protein 1 (TP53BP1) gene in breast cancer patients treated with breast-conserving surgery and whole-breast irradiation (BCS+RT). Int J Radiat Oncol Biol Phys 2009;75:S6.
17. Cao YY, Ge H, Chen LQ, Chen ZF, Wen DG, Li Y, et al. Correlation of 53BP1 and p53 polymorphisms to susceptibility to esophageal squamous cell carcinoma and gastric cardiac adenocarcinoma. Ai Zheng 2007;26:1052-7.
18. Kiyohara C, Horiuchi T, Miyake Y, Takayama K, Nakanishi Y. Cigarette smoking, TP53 Arg72Pro, TP53BP1 Asp353Glu and the risk of lung cancer in a Japanese population. Oncol Rep 2010;23:1361-8.
19. Chen K, Hu Z, Wang LE, Zhang W, El-Naggar AK, Sturgis EM, et al. Polymorphic TP53BP1 and TP53 gene interactions associated with risk of squamous cell carcinoma of the head and neck. Clin Cancer Res 2007;13:4300-5.
20. Lim GCC, Halimah Y. Second Report of the National Cancer Registry. Cancer Incidence in Malaysia 2003. Kuala Lumpur: National Cancer Registry, 2004.
21. Naidu R, Har YC, Taib NA. Polymorphism of FGFR4 Gly388Arg does not confer an increased risk to breast cancer development. Oncol Res 2009;18:65-71.
22. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer I. Histopathology 1991;19:403-10.
23. Bloom HG, Richardson WW. Histological grading and prognosis. Br J Cancer 1957;11:359-77.
24. Breast. AJCC Cancer Staging Manual. In: American Joint Committee on Cancer, 6th ed. New York: Springer, 2002:171-80.
25. Singletary E, Allred C, Ashley P, Bassett L, Berry D, Bland K, et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 2002;20:3628-36.
26. Naidu R, Har YC, Taib NA. P27 V109G Polymorphism is associated with lymph node metastases but not with increased risk of breast cancer. J Exp Clin Cancer Res 2007;26:133-40.